TSX open
Loading markets…

Advertisement

Stocks/NASDAQ/SYRE

Spyre Therapeutics Inc. (SYRE : NASDAQ)

Common Stock

$92.95

USD

+1.55 (1.70%)

Last updated: 2026-10-21

Follow SYRE

SYRE

Spyre Therapeutics Inc.

Source:WealthAwesomeWealthAwesome
↑ $4.24 (4.78%)
30 day period
$78.63$85.91$93.19Sep 10Oct 1Oct 21

Performance

1 Day

+1.70%

1 Week

+18.21%

1 Month

+1.00%

YTD

+6.24%

Key Statistics

Market Cap

$8.69B

52W High

$110.17

52W Low

$21.14

P/E Ratio

-

50 Day MA

$91.43

200 Day MA

$70.97

Beta

3.11

Dividend Yield

-

Advertisement

Technical Indicators

Price vs 50-Day SMA

↑Above 50 SMA

Price vs 200-Day SMA

↑Above 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
10/21/2026$92.78$95.17$92.31$92.95$92.951,043,487
10/20/2026$85.12$93.22$85.08$91.40$91.401,703,776
10/19/2026$82.29$86.05$80.94$84.72$84.721,271,135
10/16/2026$80.21$80.52$78.13$79.90$79.901,273,300
10/15/2026$76.87$80.88$76.87$80.10$80.101,146,176
10/14/2026$80.13$82.45$77.95$78.63$78.631,624,638
10/13/2026$85.12$85.32$80.45$80.45$80.451,441,011
10/12/2026$86.30$86.62$84.21$85.90$85.90873,506
10/9/2026$79.90$86.22$78.73$85.69$85.691,116,400
10/8/2026$79.58$80.91$77.05$79.90$79.902,326,629

Analyst Price Targets

Based on 18 analysts covering SYRE · as of Oct 22, 2026

📈

Wall Street analysts forecast SYRE stock price to rise 31.6% over the next 12 months.

Consensus

Strong Buy

4.83 / 5.00

Avg. Target

US$122.33

+31.6% Upside

Previously US$120.87 on Oct 21, 2026

Current Price

US$92.95

Last close

Analyst Breakdown (18 analysts)

Strong Buy 16
Buy 1
Hold 1
Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on SYRE's historical volatility

HistoricalForecast68%95%
US$36.94US$67.13US$97.32US$127.51US$157.70US$187.89TodayJun 17Aug 20Oct 21Dec 3Jan 16Feb 28

30-Day Vol

65.5%

Annualized

90-Day Vol

66.6%

Annualized

Trend (90d)

-30.5%

Annualized drift

90d Mean

US$83.35

Expected price

HorizonExpected68% Range (1σ)
30 trading daysUS$89.63US$71.49 – US$112.37
60 trading daysUS$86.43US$62.78 – US$119.00
90 trading daysUS$83.35US$56.34 – US$123.30

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Spyre Therapeutics Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Financials

Revenue (TTM)
$0
EBITDA
$-207.82M
Profit Margin
0.00%
ROE (TTM)
-22.98%
EPS (Diluted)
-1.95
Book Value
10.84

Classification

Sector
Health Care
Industry
Biotechnology
Group
Pharmaceuticals, Biotechnology & Life Sciences

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Advertisement

Common Questions About SYRE.US

Market movers

Recent NASDAQ movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
POMPOMDOCTOR LIMITED American Depositary Shares$3.01+352.77%
MIMIMint Incorporation Limited Class A Ordinary Shares$1.09+118.80%
SHFSSHF Holdings Inc$0.15+71.52%
LESLQLeslie's, Inc.$0.07+63.06%
XHLDTEN Holdings, Inc. Common Stock$0.91+52.46%
WHLRWheeler Real Estate Investment Trust, Inc.$0.53+47.22%
SPHLSpringview Holdings Ltd Class A Ordinary Shares$3.54+45.68%
SVRNOceanPal Inc.$36.76+41.49%

SYRE.US news timeline

2 articles covering SYRE.US, most recent first

Latest

Why Spyre Therapeutics Inc. stock surged yesterday

•Stocks

Advertisement